Search the GHTC website

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

January 21, 2013 by Kim Lufkin

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Results of a first-of-its-kind clinical trial of a new tuberculosis (TB) vaccine candidate show the candidate vaccine was safe and well tolerated. However, the candidate vaccine did not prevent TB disease when administered as a boost to the currently used BCG vaccine.

The Bill & Melinda Gates Foundation has awarded the Task Force for Global Health a five-year, $28.8 million grant to establish a research support center for neglected tropical diseases.

A new article examines the challenges and opportunities ahead for scientists developing vaccines against infectious diseases such as HIV, malaria, and TB.

Scientists have demonstrated the ability to deliver a dried vaccine to the skin without a traditional needle. Researchers say that this technique would offer several benefits, including removing the need for refrigeration, providing a cheaper alternative to hypodermic needles, and reducing safety risks from needle contamination.

A new study co-edited by the World Trade Organization, World Health Organization, and World Intellectual Property Organization outlines policies needed to advance new medical and health technologies, and to ensure that they reach the people who need them.

About the author

Kim LufkinGHTC

Kim Lufkin is a communications officer at GHTC.